Ben Venue Laboratories,
Inc. Named Recipient of the Governor’s Award for Outstanding Achievement in
Environmental Stewardship
BEDFORD,
OH – December 8, 2008 – Ben Venue Laboratories, Inc. is pleased to be
the recipient of the 2008 Governor’s Award for Outstanding Achievement
in Environmental Stewardship presented by Governor Ted Strickland and
the State of Ohio Environmental Protection Agency on December 3, 2008.
The award recognizes Ben Venue for its environmental, health and safety
management system that strives to promote a safe and healthy
manufacturing environment, including brownfield reuse and
re-development, LEED (Leadership in Energy and Environmental Design)
construction design and application for Silver Certification for its
recently completed 90,000 square foot Lab and Office facility, recycling
and reuse, energy saving, and water conservation.
Coordinated by the Ohio EPA, the award seeks to acknowledge Ohio
businesses and organizations demonstrating a commitment to go above and
beyond compliance, maintain aggressive environmental performance goals,
and provide a process for communicating with others about program
activities and progress toward established goals. Submitted nominations
were rated and the Ohio EPA completed site audits with the finalists to
select the eight chosen honorees. "I'm honored to recognize these
forward-thinking award winners, which have all demonstrated cutting-edge
achievements and a commitment to environmental stewardship in Ohio,"
said Ohio EPA Director Chris Korleski in a press release issued by the
Governor’s office. Governor Ted Strickland added "These companies are
leaders in protecting Ohio's natural resources while implementing
innovative approaches that reduced the cost of doing business, improved
company efficiency, and enhanced the quality of life and the environment
in their communities. I commend their efforts," More information about
the award is available at:
http://www.epa.state.oh.us/ocapp/stewardship.html.
Ben Venue Laboratories,
Inc. Cares
Caring
for the environment is one of the many ways Ben Venue works to make a
difference. Each day, employees work to fulfill the company mission to
provide their customers with pharmaceutical products that improve
people’s health and quality of life. This commitment to others also
stems deeply into how the organization gives back to the community
through many avenues including responsible environmental stewardship.
With support from all levels of the organization, the environmental
health and safety management system continues to take on new life with
each passing year. From activities including the careful consideration
for environmentally-friendly construction design to numerous grass-roots
employee efforts, Ben Venue cares about the footprint it maintains and
the impact on the environment. Employees started a Waste Minimization
and Recycling Team in 2005 to identify routes to recycle waste streams.
Successes include saving valuable landfill space and significantly
reducing waste disposal costs. The company recycled and reused 35 tons
of material in 2005, 360 tons in 2006 and over 730 tons in 2007. A
precious-metal recycling program that began in 2007 recovered over 170
troy ounces of platinum for a return of more than $265,000. A water
reclamation system installed in 2006 saved more than 7 million gallons
of water in 2006 with a cost savings of $57,000. The most recent
accomplishment was the completion of the LEED Silver Certification
application for its newest facility, a 90,000 square foot Lab and Office
building. President and COO, Thomas Murphy stated, “This commitment is
at the heart of how we conduct business today and is sure to bring about
even greater results for the future.”
Pictured Above:
Top
Picture: EPA Director Chris Korleski, Cheryl May - Manager of EHS, and
Governor Ted Strickland
Bottom
Picture: Kevin Wemett - Government Affairs, Rob Fromuth - Sr VP
Operations, Valerie Baker - Associate Director EHS, Chris Korleski - EPA
Director, Cheryl May - Manager of EHS and Jason Kurtz - Manager of
Communications and PR
|
Ben Venue Laboratories, Inc. Dedicates New 162,000 Square-Foot
Expansion; 300 New Jobs to Bedford, Ohio
BEDFORD, OH—July 8, 2003—Ben Venue Laboratories, Inc. today celebrated the dedication of the latest expansion of its Bedford, Ohio pharmaceutical manufacturing facility. The new facility represents an addition of 162,000 square feet, and a capital investment of $82 million. The company has spent over $150 million in the last three years at its Bedford facility on further expansion and improvements.
“Ben Venue continues to grow to position itself to supply the expanding market for injectable pharmaceuticals,” said Thomas Russillo, President & COO. “We are proud to be the largest biotech employer in Northern Ohio and are creating about 300 new jobs with this expansion. We expect to continue growing even further.”
“Expansion of the Ben Venue facility underlines our strategic focus on the US market as an essential driver for continuous growth of the company,” stated Dr. Hans-Juergen Leuchs, Head of Corporate Board Division Operations and Member of the Board of Managing Directors at Boehringer Ingelheim.
With the new facility, Ben Venue now comprises 500,000
square feet at its Bedford location. The company is the
world’s largest and most experienced contract developer
and manufacturer of sterile pharmaceuticals. Its operations
also include the Bedford Laboratories division, the third
largest supplier of generic injectable products to theUS
hospital market.
The new facility includes two new continuous filling lines with robotic traying that can accommodate either lyophilized (freeze-dried) or liquid products. It also includes six new 400 square foot lyophilizers with clean-in-place/steam-in-place capability, new sterilization equipment and a 10,000 unit per hour packaging line.
Ben Venue Laboratories, Inc. is a subsidiary of Boehringer Ingelheim Corporation based in Ridgefield, CT, and a member of the Boehringer Ingelheim group of companies, headquartered in Ingelheim, Germany.
The Boehringer Ingelheim group of companies ranks among the 20 leading pharmaceutical corporations in the world and has 156 affiliated companies in 44 countries worldwide. Focusing on human pharmaceuticals and animal health, it posted revenues of $7.2 billion in 2002.
Since 1885, Boehringer Ingelheim has been a privately-held company with a long history of successfully marketed pharmaceutical innovations. Research and development, production and distribution facilities are located around the globe. In 2002, Boehringer Ingelheim’s R&D spending was more than $1.2 billion U.S. which is about a fifth of net sales in Prescription Medicines.
For more information on Boehringer Ingelheim, please see the international Internet website
www.boehringer-ingelheim.com.
Ben Venue Laboratories, Inc. Awarded
National Cancer Institute Contract
BEDFORD, OH—March 3, 2003—Ben Venue Laboratories, Inc. has again been awarded a five year contract with the National Cancer Institute (NCI) to develop and manufacture investigational compounds that will be studied in a variety of tumor types. This award is one of an uninterrupted series of contracts that have been in place at Ben Venue since the late 1960’s,
and is one of the longest running in NCI history. The amount
of the award is $8 million and the term of the contract
is from March 3, 2003 through February 29, 2008.
Ben Venue's NCI contract supports process development/scale-up, specialized process and analytical method development/validation as well as manufacturing of investigational anti-tumor agents. The NCI issued requests for proposals at two levels of effort, and it was expected that contracts would be awarded to two different manufacturers. Ben Venue bid on and was awarded both levels.
"Ben Venue is very proud to have been awarded this contract," said
Thomas Russillo, President and COO. "It gives us the opportunity
to assist in making promising new research therapies available
for cancer patients. Through our contracts in the past,
we have participated in the development of many of the
leading oncologic agents used today, including methotrexate,
daunorubicin, paclitaxel, cisplatin, BiCNU, dacarbazine
(DTIC), Fludara and calcium leucovorin."
|